{"protocolSection": {"identificationModule": {"nctId": "NCT01193049", "orgStudyIdInfo": {"id": "0000-175"}, "secondaryIdInfos": [{"id": "2010-020518-27", "type": "EUDRACT_NUMBER", "domain": "From the European Union Drug Regulatory Authorities Clinical Trial System"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study on the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics (MK-0000-175)", "officialTitle": "A Two-Part, Randomized Clinical Trial to Study the Effects of a Single Dose of Prednisone on Biomarkers of Allergen Responses in Asthmatics"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-08"}, "primaryCompletionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-30", "studyFirstSubmitQcDate": "2010-08-30", "studyFirstPostDateStruct": {"date": "2010-09-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-06-27", "resultsFirstSubmitQcDate": "2012-06-27", "resultsFirstPostDateStruct": {"date": "2012-08-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-03", "lastUpdatePostDateStruct": {"date": "2015-09-04", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the relationship between upper and lower airway allergen-induced cytokine responses in mild asthmatics by attempting to demonstrate the following: 1) a positive correlation between allergen-induced Type 2 T-helper cell (Th2) cytokines (interleukins 5 and 13) in sputum and nasal exudates; and 2) a positive correlation between effects of prednisone versus placebo on Th2 cytokines in sputum and nasal exudates."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Nasal Allergen Challenge, Inhaled Allergen Challenge, Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 11, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Prednisone, then Placebo", "type": "EXPERIMENTAL", "description": "Prednisone in the first crossover treatment period and placebo in the second crossover treatment period", "interventionNames": ["Drug: Prednisone", "Drug: Placebo"]}, {"label": "Placebo, then Prednisone", "type": "EXPERIMENTAL", "description": "Placebo in the first crossover treatment period and prednisone in the second crossover treatment period", "interventionNames": ["Drug: Prednisone", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Prednisone", "description": "Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period", "armGroupLabels": ["Placebo, then Prednisone", "Prednisone, then Placebo"]}, {"type": "DRUG", "name": "Placebo", "description": "Matching placebo tablets as a single oral dose on Day 1 of each study period", "armGroupLabels": ["Placebo, then Prednisone", "Prednisone, then Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Geometric Mean Fold Change From Baseline in Interleukin-5 (IL-5) Concentration From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, nasal exudates (NE) and sputum (SP) were collected, then the concentrations of IL-5 were determined from NE and SP collected after 7 hours and previously at baseline (BL), to derive the fold change (FC) from BL for each participant. The geometric mean (GM) was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Interleukin-13 (IL-13) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-13 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}], "secondaryOutcomes": [{"measure": "Geometric Mean Fold Change From Baseline in Thymus and Activation Regulated Chemokine (TARC) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of TARC were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Eotaxin-3 From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of Eotaxin-3 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Change in Vibration Response Imaging (VRI) After Metacholine Exposure", "description": "One hour before treatment with prednisone/placebo, participants inhaled for 2 minutes a nebulised solution of metacholine (0.13 ml/min); then one hour after prednisone/placebo treatment were challenged with allergens. From 1 to 7 hours after allergen challenge, ventilatory heterogeneity was assessed by Vibration Response Imaging (VRI) by monitoring the following: inspiration/expiration (I/E) amplitude ratio, I/E duration ratio, synchrony duration, and quantitative lung data.", "timeFrame": "From 1 to 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in RNA Expression for Genes Encoding IL-5 and IL-13 From Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, SP were collected, then the RNA expression profiles of IL-5 and IL-13 genes were determined from SP collected after 7 hours and previously at baseline, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Interleukin-17 (IL-17) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-17 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Interleukin-1\u03b2 (IL-1\u03b2) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-1\u03b2 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Macrophage Inflammatory Protein-1\u03b2 (MIP-1\u03b2) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of MIP-1\u03b2 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Thymic Stromal Lymphopoietin (TSLP) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of TSLP were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Interleukin-23 (IL-23) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-23 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was plan to be determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Cytokines From Bronchoalveolar Lavage Fluid (BALf)", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 23 hours had elapsed, BALf were collected, then the concentrations of IL-5, IL-13, and TARC were determined from BALf collected after 23 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 23 hours post-allergen challenge"}, {"measure": "Geometric Mean Fold Change From Baseline in Nasal and Bronchial Eicosanoids and Leukotrienes at 7 Hours Post-allergen Challenge.", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then prostaglandin and leukotriene concentrations were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "timeFrame": "Baseline and 7 hours post-allergen challenge"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has a clinical history of mild to moderate asthma for at least 6 months, but otherwise is in good health\n* Participant with allergic rhinitis and asthma has a history of nonseasonal airway symptoms in response to aeroallergens OR has seasonal symptoms but can be evaluated out-of-season\n* Is clinically stable and free of respiratory infection or change in allergen exposure for at least 4 weeks prior to start of study\n\nExclusion Criteria:\n\n* Has intolerance to the study drug, inhaled salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue medication\n* Has intolerance to lidocaine/lignocaine, sedatives, atropine or glycopyrrolate, or any other medication associated with bronchoscopy\n* Has taken oral parenteral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 5 weeks of screening and/or during the study\n* Has recent (4 weeks) or ongoing upper or lower respiratory tract infection\n* Has active allergic rhinitis at screening\n* Has received a vaccination within 3 weeks of screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Prednisone, Then Placebo", "description": "Prednisone in the first double blind treatment period and placebo in the second double blind treatment period"}, {"id": "FG001", "title": "Placebo, Then Prednisone", "description": "Placebo in the first double blind treatment period and prednisone in the second double blind treatment period"}], "periods": [{"title": "Period 1: Placebo Run-In", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout 1 : 21 Day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2 : Double Blind Crossover", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Washout 2 : 21 Day Washout", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 3 : Double Blind Crossover", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Participants", "description": "All randomized participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.5", "spread": "7.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Geometric Mean Fold Change From Baseline in Interleukin-5 (IL-5) Concentration From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, nasal exudates (NE) and sputum (SP) were collected, then the concentrations of IL-5 were determined from NE and SP collected after 7 hours and previously at baseline (BL), to derive the fold change (FC) from BL for each participant. The geometric mean (GM) was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.16", "lowerLimit": "1.25", "upperLimit": "3.74"}, {"groupId": "OG001", "value": "8.60", "lowerLimit": "3.82", "upperLimit": "19.34"}]}]}, {"title": "Nasal Exudate", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.69", "lowerLimit": "0.88", "upperLimit": "3.26"}, {"groupId": "OG001", "value": "8.63", "lowerLimit": "4.45", "upperLimit": "16.77"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM Fold Reduction (FR) is the GM of individual FC(Prednisone)/FC (Placebo) from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.25", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "0.46"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR is the GM of individual FC(Prednisone)/FC(Placebo) from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "1-sided p value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo : NE", "paramValue": "0.20", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.13", "ciUpperLimit": "0.30"}, {"groupIds": ["OG001"], "groupDescription": "Correlation between SP and NE of FC from BL in IL-5 after placebo treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.553", "pValueComment": "Unadjusted for Baseline and Period Effects", "statisticalMethod": "Pearson's correlation coefficient", "paramType": "Correlation FC from BL: SP vs NE", "paramValue": "0.20"}, {"groupIds": ["OG000"], "groupDescription": "Correlation between SP and NE of FR from placebo in IL-5 after prednisone treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.964", "pValueComment": "Unadjusted for Baseline and Period Effects", "statisticalMethod": "Pearson's correlation coefficient", "paramType": "Correlation FR from Placebo :SP vs NE", "paramValue": "-0.02"}]}, {"type": "PRIMARY", "title": "Geometric Mean Fold Change From Baseline in Interleukin-13 (IL-13) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-13 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.57", "lowerLimit": "1.21", "upperLimit": "2.04"}, {"groupId": "OG001", "value": "5.86", "lowerLimit": "2.57", "upperLimit": "13.36"}]}]}, {"title": "Nasal Exudate", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.02", "lowerLimit": "0.65", "upperLimit": "1.58"}, {"groupId": "OG001", "value": "3.29", "lowerLimit": "1.82", "upperLimit": "5.95"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR is the GM of individual FC(Prednisone)/FC (Placebo) from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.009", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.27", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.12", "ciUpperLimit": "0.62"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR is the GM of individual FC Prednisone)/FC(Placebo) from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo : NE", "paramValue": "0.31", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.22", "ciUpperLimit": "0.43"}, {"groupIds": ["OG001"], "groupDescription": "Correlation between SP and NE of FC from BL in IL-13 after placebo treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.962", "pValueComment": "Unadjusted for Baseline and Period Effects", "statisticalMethod": "Pearson's correlation coefficient", "paramType": "Correlation FC from BL: SP vs NE", "paramValue": "-0.02"}, {"groupIds": ["OG000"], "groupDescription": "Correlation between SP and NE of FR from placebo in IL-13 after prednisone treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.83", "pValueComment": "Unadjusted for Baseline and Period Effects", "statisticalMethod": "Pearson's correlation coefficient", "paramType": "Correlation FR from Placebo: SP vs NE", "paramValue": "0.07"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Thymus and Activation Regulated Chemokine (TARC) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of TARC were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "lowerLimit": "1.22", "upperLimit": "2.17"}, {"groupId": "OG001", "value": "2.04", "lowerLimit": "1.21", "upperLimit": "3.46"}]}]}, {"title": "Nasal Exudates", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.33", "lowerLimit": "0.88", "upperLimit": "2.01"}, {"groupId": "OG001", "value": "1.22", "lowerLimit": "0.96", "upperLimit": "1.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.258", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.80", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.43", "ciUpperLimit": "1.47"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.681", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: NE", "paramValue": "1.08", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.80", "ciUpperLimit": "1.46"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Eotaxin-3 From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of Eotaxin-3 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.30", "lowerLimit": "0.67", "upperLimit": "2.51"}, {"groupId": "OG001", "value": "2.14", "lowerLimit": "1.41", "upperLimit": "3.24"}]}]}, {"title": "Nasal Exudates", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.86", "lowerLimit": "0.56", "upperLimit": "1.31"}, {"groupId": "OG001", "value": "1.35", "lowerLimit": "0.66", "upperLimit": "2.74"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.117", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo:SP", "paramValue": "0.61", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.30", "ciUpperLimit": "1.24"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: NE", "paramValue": "0.64", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.47", "ciUpperLimit": "0.86"}]}, {"type": "SECONDARY", "title": "Change in Vibration Response Imaging (VRI) After Metacholine Exposure", "description": "One hour before treatment with prednisone/placebo, participants inhaled for 2 minutes a nebulised solution of metacholine (0.13 ml/min); then one hour after prednisone/placebo treatment were challenged with allergens. From 1 to 7 hours after allergen challenge, ventilatory heterogeneity was assessed by Vibration Response Imaging (VRI) by monitoring the following: inspiration/expiration (I/E) amplitude ratio, I/E duration ratio, synchrony duration, and quantitative lung data.", "populationDescription": "As all VRI results showed no allergen or treatment-related signals these results are not presented.", "reportingStatus": "POSTED", "timeFrame": "From 1 to 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in RNA Expression for Genes Encoding IL-5 and IL-13 From Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, SP were collected, then the RNA expression profiles of IL-5 and IL-13 genes were determined from SP collected after 7 hours and previously at baseline, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "IL-5", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.87", "lowerLimit": "3.20", "upperLimit": "7.39"}, {"groupId": "OG001", "value": "7.37", "lowerLimit": "5.96", "upperLimit": "9.11"}]}]}, {"title": "IL-13", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.90", "lowerLimit": "2.42", "upperLimit": "3.48"}, {"groupId": "OG001", "value": "3.93", "lowerLimit": "3.02", "upperLimit": "5.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) for IL-5.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.010", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: IL-5", "paramValue": "1.51", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.15", "ciUpperLimit": "1.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC(Prednisone)/FC (Placebo) for IL-13.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.020", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: IL-13", "paramValue": "1.35", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.07", "ciUpperLimit": "1.71"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Interleukin-17 (IL-17) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-17 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "lowerLimit": "0.58", "upperLimit": "0.80"}, {"groupId": "OG001", "value": "0.83", "lowerLimit": "0.71", "upperLimit": "0.98"}]}]}, {"title": "Nasal Exudates", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.84", "lowerLimit": "0.48", "upperLimit": "1.46"}, {"groupId": "OG001", "value": "1.23", "lowerLimit": "1.14", "upperLimit": "1.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) in IL-17 from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.119", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.82", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.62", "ciUpperLimit": "1.09"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) in IL-17 from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.103", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: NE", "paramValue": "0.68", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.41", "ciUpperLimit": "1.14"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Interleukin-1\u03b2 (IL-1\u03b2) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-1\u03b2 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.80", "lowerLimit": "0.55", "upperLimit": "1.17"}, {"groupId": "OG001", "value": "1.34", "lowerLimit": "0.86", "upperLimit": "2.09"}]}]}, {"title": "Nasal Exudates", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "lowerLimit": "0.14", "upperLimit": "0.27"}, {"groupId": "OG001", "value": "0.39", "lowerLimit": "0.24", "upperLimit": "0.63"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) in IL-1\u03b2 from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.60", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.46", "ciUpperLimit": "0.77"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC(Prednisone)/FC (Placebo) in IL-1\u03b2 from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.036", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: NE", "paramValue": "0.49", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.26", "ciUpperLimit": "0.93"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Macrophage Inflammatory Protein-1\u03b2 (MIP-1\u03b2) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of MIP-1\u03b2 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was determined by averaging FC from BL for all analyzed participants.", "populationDescription": "All randomized participants", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Fold Change", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "classes": [{"title": "Sputum", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.35", "lowerLimit": "0.75", "upperLimit": "2.43"}, {"groupId": "OG001", "value": "1.92", "lowerLimit": "0.94", "upperLimit": "3.93"}]}]}, {"title": "Nasal Exudates", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.73", "lowerLimit": "0.47", "upperLimit": "1.13"}, {"groupId": "OG001", "value": "1.19", "lowerLimit": "0.70", "upperLimit": "2.01"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC(Prednisone)/FC (Placebo) in MIP-1\u03b2 from SP.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.143", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: SP", "paramValue": "0.70", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "1.24"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "GM FR from Placebo is the GM of individual FC (Prednisone)/FC (Placebo) in MIP-1\u03b2 from NE.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.056", "pValueComment": "1-sided p-value, \u03b1 = 0.05", "statisticalMethod": "ANOVA", "paramType": "GM FR from Placebo: NE", "paramValue": "0.61", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.37", "ciUpperLimit": "1.02"}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Thymic Stromal Lymphopoietin (TSLP) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of TSLP were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "populationDescription": "As TSLP levels were too low to detect, this analysis was not performed and results are not presented.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Interleukin-23 (IL-23) From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then the concentrations of IL-23 were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was plan to be determined by averaging FC from BL for all analyzed participants.", "populationDescription": "As IL-23 levels were too low to detect, this analysis was not performed and results are not presented.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Cytokines From Bronchoalveolar Lavage Fluid (BALf)", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 23 hours had elapsed, BALf were collected, then the concentrations of IL-5, IL-13, and TARC were determined from BALf collected after 23 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "populationDescription": "As concentrations of cytokines were below the lower limit of quantitation this analysis was not performed, and results are not presented.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 23 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Geometric Mean Fold Change From Baseline in Nasal and Bronchial Eicosanoids and Leukotrienes at 7 Hours Post-allergen Challenge.", "description": "Participants were treated with either prednisone or placebo, followed 1 hour later by nasal allergen challenge and then inhaled allergen challenge. After 7 hours had elapsed, NE and SP were collected, then prostaglandin and leukotriene concentrations were determined from NE and SP collected after 7 hours and previously at BL, to derive the FC from BL for each participant. The GM was planned to be determined by averaging FC from BL for all analyzed participants.", "populationDescription": "As this same approach in a parallel study was unfruitful, these data were not pursued, and results are not presented.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 7 hours post-allergen challenge", "groups": [{"id": "OG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone"}, {"id": "OG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All participants in this crossover study received both prednisone and placebo.", "eventGroups": [{"id": "EG000", "title": "Prednisone", "description": "All participants who received at least one dose of prednisone", "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 1, "otherNumAtRisk": 11}, {"id": "EG001", "title": "Placebo", "description": "All participants who received at least one dose of placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 4, "otherNumAtRisk": 11}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Influenza Like Illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 11}]}, {"term": "Seasonal Allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Wrist Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 14.1", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 11}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp and Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000011241", "term": "Prednisone"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018931", "term": "Antineoplastic Agents, Hormonal"}, {"id": "D000000970", "term": "Antineoplastic Agents"}], "browseLeaves": [{"id": "M14121", "name": "Prednisone", "asFound": "Min", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20966", "name": "Antineoplastic Agents, Hormonal", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}